

Chara Papadaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4593553/publications.pdf>

Version: 2024-02-01

40
papers

972
citations

516561

16
h-index

454834

30
g-index

41
all docs

41
docs citations

41
times ranked

1518
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. PLoS ONE, 2008, 3, e3695.	1.1	121
2	Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in 2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. PLoS ONE, 2011, 6, e15980.	1.1	114
3	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Research, 2018, 20, 72.	2.2	69
4	ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 663-671.	0.5	58
5	PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. British Journal of Cancer, 2014, 111, 1757-1764.	2.9	53
6	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. Cancers, 2020, 12, 376.	1.7	52
7	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome. PLoS ONE, 2013, 8, e84604.	1.1	48
8	Regional distribution and cell type-specific expression of the mouse F3 axonal glycoprotein: A developmental study. , 1999, 413, 357-372.		42
9	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. Oncotarget, 2019, 10, 966-981.	0.8	38
10	Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen. Clinical Cancer Research, 2009, 15, 3827-3833.	3.2	35
11	Transcriptional Repressor Erf Determines Extraembryonic Ectoderm Differentiation. Molecular and Cellular Biology, 2007, 27, 5201-5213.	1.1	34
12	Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. British Journal of Cancer, 2011, 104, 316-323.	2.9	31
13	Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP2A, TOP2B and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. PLoS ONE, 2013, 8, e74611.	1.1	31
14	The RAS-dependent ERF Control of Cell Proliferation and Differentiation Is Mediated by c-Myc Repression. Journal of Biological Chemistry, 2007, 282, 30285-30294.	1.6	24
15	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Translational Lung Cancer Research, 2021, 10, 3538-3549.	1.3	21
16	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PLoS ONE, 2021, 16, e0252537.	1.1	20
17	Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer. Clinical Cancer Research, 2011, 17, 165-173.	3.2	19
18	Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 767-775.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. <i>Cancers</i> , 2020, 12, 1013.	1.7	17
20	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. <i>Cancers</i> , 2020, 12, 1282.	1.7	17
21	Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. <i>Pharmacogenomics Journal</i> , 2017, 17, 506-514.	0.9	16
22	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2058.	1.7	14
23	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 668534.	1.6	14
24	ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Cancer Investigation</i> , 2015, 33, 107-113.	0.6	13
25	The upstream regulatory region of the gene for the human homologue of the adhesion molecule TAG-1 contains elements driving neural specific expression in vivo. <i>Molecular Brain Research</i> , 2003, 118, 91-101.	2.5	10
26	Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1518-1526.	1.3	10
27	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 1988.	1.8	9
28	TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. <i>Cancers</i> , 2022, 14, 1053.	1.7	7
29	Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14045-e14045.	0.8	3
30	Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 8257-8271.	0.9	3
31	MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. <i>Biomedicines</i> , 2021, 9, 421.	1.4	2
32	Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9099-9099.	0.8	2
33	MicroRNAs involved in immune response as prognostic markers in early and metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15528-e15528.	0.8	2
34	Intergration of common clinical and laboratory parameters for predictive modeling of outcome with immune checkpoint inhibitors (ICIs) in patients (pts) with Non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21609-e21609.	0.8	2
35	Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 901-913.	0.5	1
36	Mir-34a as predictor of immunotherapy efficacy in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21191-e21191.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Investigation of TLR4 and pSTAT3 expression on tumor and immune cells in the peripheral blood (PB) of patients with breast cancer (BC).. Journal of Clinical Oncology, 2021, 39, e15015-e15015.	0.8	0
38	Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-ii, TOPO-iib, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide.. Journal of Clinical Oncology, 2013, 31, 7594-7594.	0.8	0
39	PKM2 and CD44 tumoral expression to predict the effectiveness of front-line paclitaxel and carboplatin chemotherapy in epithelial ovarian cancer.. Journal of Clinical Oncology, 2015, 33, e16564-e16564.	0.8	0
40	Cancer cachexia syndrome in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a single-institution, prospective, observational study.. Journal of Clinical Oncology, 2020, 38, e21644-e21644.	0.8	0